DrugLinx - Pharmaceutical News Daily

Pharma

Become a Member Today!

Home
General Pharma

Messages

Conferences

Jobs

Newsletters

My Library

Topics in
Pharma

Biotechnology

Drug Trials

Popular Press

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

MDLinx Email Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 email addresses.
*From Email:
*To Email:
To Email:
To Email:
To Email:
To Email:

AVI BioPharma Under Contract with U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu
AVI BioPharma, Inc. , a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu. [more...]

AVI BioPharma

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine

Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics

Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Sponsor